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Abstract
Background:  Epigenetic alterations and loss of heterozygosity are mechanisms of tumor
suppressor gene inactivation. A new carcinogenic pathway, targeting the RAS effectors has recently
been documented. RASSF1A, on 3p21.3, and NORE1A, on 1q32.1, are among the most important,
representative RAS effectors.
Methods: We screened the 3p21 locus for the loss of heterozygosity and the hypermethylation
status of RASSF1A, NORE1A and BLU (the latter located at 3p21.3) in 41 neuroblastic tumors. The
statistical relationship of these data was correlated with CASP8 hypermethylation. The expression
levels of these genes, in cell lines, were analyzed by RT-PCR.
Results: Loss of heterozygosity and microsatellite instability at 3p21 were detected in 14% of the
analyzed tumors. Methylation was different for tumors and cell lines (tumors: 83% in RASSF1A, 3%
in NORE1A, 8% in BLU and 60% in CASP8; cell lines: 100% in RASSF1A, 50% in NORE1A, 66% in
BLU and 92% in CASP8). In cell lines, a correlation with lack of expression was evident for
RASSF1A, but less clear for NORE1A, BLU and CASP8. We could only demonstrate a statistically
significant association between hypermethylation of RASSF1A and hypermethylation of CASP8,
while no association with MYCN amplification, 1p deletion, and/or aggressive histological pattern
of the tumor was demonstrated.
Conclusion: 1) LOH at 3p21 appears in a small percentage of neuroblastomas, indicating that a
candidate tumor suppressor gene of neuroblastic tumors is not located in this region.
2) Promoter hypermethylation of RASSF1A and CASP8 occurs at a high frequency in 
neuroblastomas.
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Background
Neuroblastic tumors are childhood embryonal neoplasms
composed of neural crest-derived neuroectodermal cells,
which migrate to the adrenal medulla and sympathetic
nervous system[1]. According to the schwannian stroma
component, these tumors are classified as neuroblastoma,
nodular or intermixed ganglioneuroblastoma, and gangli-
oneuroma[1]. Neuroblastoma is the most common
extracranial malignant pediatric solid tumor. The genetic
alterations most frequently found in neuroblastoma are
MYCN amplification and 1p36 allelic loss, both of them
associated with a poor prognosis. Gains of chromosomes
4q, 6p, 7q, 11q and 18q, amplification of MDM2 and
MYCL genes, 17q trisomy and allelic losses at 11q, 14q
and 10q have also been described[2].
Allelic losses on the short arm of chromosome 3 have
been found in many sporadic human cancers, including
lung, kidney, breast, ovarian and neural crest-derived
tumors[3]. Loss of heterozygosity (LOH) studies have
identified several distinct 3p loci which are likely to con-
tain the tumor suppressor genes: 3p12, 3p14, 3p21.3 and
3p25-26. Overlapping homozygous deletions in lung and
breast tumor cell lines have identified the minimal
deleted region to 120 kb in 3p21.3 [3-6]. Eight genes were
located within this region including the alpha-2 delta-2
calcium channel subunit, PL6, 101F6, NPRL2/G21, BLU,
RASSF1, FUS1 and LUCA2[5].
RASSF1A (Ras Association Domain Family Protein 1 iso-
form A) was described by Dammann et al[7] as a Ras effec-
tor located at 3p21.3 and its function was thought to be in
modulating the Ras-mediated apoptotic response. This
gene is also involved in maintaining cytoskeletal integ-
rity[8] and regulating mitosis[9]. RASSF1A is subject to
promoter hypermethylation in several neoplasias such as
lung, breast, ovarian and kidney cancers and in pediatric
tumors[7,10-12].
BLU shares 30–32% identity with proteins of the MTG/
ETO family of transcription factors and the suppressins,
which are thought to regulate cell cycle entry[3]. BLU pro-
moter hypermethylation has been described in lung,
breast, kidney, and neuroblastoma cell lines[3]. In these
cases, hypermethylation was correlated with down regula-
tion of BLU expression. A correlation between methyla-
tion of BLU and RASSF1A has been described in
NSCLC[3].
Another Ras effector described recently is the NORE1[13].
NORE1, in 1q32.1, is homologous to the previously
described mouse Nore1 gene and exists in the 3 alterna-
tively spliced isoforms, NORE1Aα, NORE1Aβ and
NORE1B[14]. NORE1 and RASSF1A efficiently form
homodimers and heterodimers, with each other, through
their non-homologous aminoterminal segments. The
ability of RASSF1A to form heterodimers with NORE1,
thereby associating with Ras-like GTPases, may be impor-
tant for its function as a tumor suppressor gene[15].
NORE1A shares sequence similarity and genomic struc-
ture with RASSF1A[15]. Promoter hypermethylation of
NORE1A has been described in lung, breast, colon, kidney
and Wilms' tumors[14,16].
Apoptotic defects may be responsible for tumor forma-
tion, progression and resistance to drugs in neuroblast-
oma. The best known apoptotic defect in neuroblastoma
tumors and cell lines is the down regulation of CASP8,
which strongly correlates with TRAIL unresponsiveness.
CASP8, located at chromosome 2q33-q34, encodes cas-
pase 8, an initiator caspase that plays an important role in
the Fas-Fas ligand pathway[17,18]. Alterations of these
genes have been described in several neoplasias, such as
mutations in colon cancer and promoter hypermethyla-
tion in medulloblastomas and neuroblastomas [19-21].
In this study we analyzed: 1) LOH and MSI (microsatellite
instability) at chromosome 3p21 in neuroblastic tumors;
2) promoter methylation of the RASSF1A, NORE1A, BLU
and CASP8 genes, determined in neuroblastic tumors and
neuroblastoma cell lines; and 3) gene expression and its
correlation with promoter methylation upstream of these
genes, analyzed in neuroblastoma cell lines.
Methods
Tumor samples
Forty one neuroblastic tumors (26 neuroblastomas, 12
ganglioneuroblastomas and 3 ganglioneuromas) were
used for this study (Table 1). All tumors were frozen and
stored at -80°C immediately after surgical extraction.
DNA isolated from blood samples of 21 patients was used
as negative control for the LOH analysis. Samples were
collected at Hospital La Paz, Madrid, Spain. Clinicopatho-
logical sample data included: patient age and sex, tumor
location, diagnosis, Shimada's index, and cell line prolif-
eration index (Ki67).
Cell lines
Neuroblastoma cell lines SK-N-DZ, SK-N-SH, SK-N-Be(2),
SK-N-FI, BE(2)C, and MC-IXC were purchased from the
American Type Culture Collection (ATCC, Manassas, VA),
and IMR-32, Kelly, SIMA, SH-SY5Y, SK-N-MC, and MHH-
NB-11 were purchased from the Deutsche Sammlung von
Mikroorganismen und Zellkuturen Gmbh (DSMZ,
Braunchsweig, Germany).
Nucleic acids extraction
DNA from tumor specimens was isolated by phenol-chlo-
roform extraction. Tissues were resuspended with 1 ml
lysis solution buffer (0.5 M NaCl, 50 mM Tris-HCl pH 7.6,BMC Cancer 2006, 6:254 http://www.biomedcentral.com/1471-2407/6/254
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50 mM EDTA, and 0.5% SDS) and incubated with 20 µl
proteinase K (20 mg/ml) at 56°C, overnight. Next, 0.4 ml
saturated NaCl was added to the mixture, the sample
shaken, and spun at 13.000 rpm for 10 min. The superna-
tant was transferred to a new tube, and DNA purified by
phenol-chloroform extraction and precipitated by adding
2 volumes of absolute ethanol at -80°C. The DNA was
washed twice with 70% ethanol, dried, and resuspended
with 200–500 µl Tris-EDTA Buffer (10 mM Tris-HCl, 1
mM EDTA, pH 8).
DNA from cell lines was extracted using the Wizard
Genomic DNA Purification Kit (Promega Corporation,
Madison, USA), following to the manufacturer's protocol.
RNA from cell lines was extracted with the QuickPrep™
Total RNA Extraction Kit (Amersham Biosciences, Buck-
inghamshire, UK), following to the manufacturer's
instructions.
Table 1: Clinico-pathological and genetic data of 41 neuroblastic tumors.
Tumor Age Sex Localization Diagnosis Shimada Histology Ki 67 LOH 1p MYCN amp.
1 3 y M Mediastinum GN n.a. 1% n.a. n.a.
17 13 y M Mediastinum GN Stroma rich. Dif. Low MKI. 1% n.a. n.a.
94 4 y M Suprarenal GN Stroma rich. Dif. Low MKI. 15% n.a. n.a.
3 5 y M Suprarenal GNB Stroma rich. Dif. Low MKI. 5% n.a. n.a.
5 3 y F Suprarenal GNB Stroma rich. Nodular 5% NO NO
7 3 y F Retroperitoneum GNB Stroma rich. Mixed 2% NO NO
8 1 y F Suprarenal GNB Stroma rich. Nodular n.a. NO YES (10 copies)
9 7 y M n.a. GNB Stroma rich. Dif. Low MKI. 10% NO NO
10 4 y M Retroperitoneum GNB Stroma rich. Dif. Mild MKI. 15% YES NO
61 1 y F Mediastinum GNB Stroma rich. Dif. Low MKI. 10% n.a. NO
82 2 y M Retroperitoneum GNB Stroma rich. Nodular n.a. NO NO
83 6 y V Mediastinum GNB Stroma rich. Nodular 15% NO NO
86 2 y F Retroperitoneum GNB Stroma rich. Dif. Low MKI. 15% n.a. YES (10–50 copies)
92 6 y M Mediastinum GNB Stroma rich. Nodular 15% NO NO
107 1 y M Thoracic-abdominal GNB Stroma rich. Mixed 5% YES NO
12 2 m F Suprarenal NB Stroma poor. Undif. Mild MKI. 50% NO YES (20 copies)
13 11 m M Abdominal NB Stroma poor. Undif. High MKI. 60% NO NO
14 2 y M Retroperitoneum NB Stroma poor. Dif. Low MKI. 40–
50%
YES YES (50 copies)
15 3 y M Suprarenal NB Stroma poor. Dif. Mild MKI. 40–
50%
NO NO
16 9 y M Mediastinum NB Stroma poor. Undif. High MKI. 60% NO NO
18 6 y F Thoracic-abdominal NB Stroma poor. Undif. Mild MKI. 60% YES NO
33 9 y M Suprarenal NB Stroma poor. Undif. High MKI. 70% NO NO
37 2 w F Retroperitoneum NB Stroma Poor. Undif. Low MKI. 10% NO NO
34 2 m F Mediastinum NB Stroma poor. Dif. 15% YES NO
45 3 w F Suprarenal NB Stroma poor. Undif. Low MKI. 10% YES NO
48 7 m F Paraaortic NB Stroma rich. Dif Low MKI. 5% n.a. NO
51 4 w M Suprarenal NB Stroma poor. Dif. 20% NO NO
52 1 m F Suprarenal NB Stroma poor. Undif. Low MKI. 10% n.a. NO
63 5 m M Suprarenal NB Stroma poor. Undif. 40% NO NO
64 2 y M Suprarenal NB Stroma poor. Undif. n.a. n.a. NO
73 2 y F Suprar. retroper NB Stroma poor. Undif. 85% YES YES
77 4 y M Retroperitoneum NB Stroma poor. Undif. 25% NO NO
85 4 y M Suprarenal NB Stroma poor. Undif. Mild MKI. 30% n.a. NO
87 3 y M Hypochondrium NB Stroma poor. Undif. High MKI. 30% n.a. YES (10 copies)
90 12 y n.a. Brain NB n.a. n.a. n.a. n.a.
91 3 y F Retroperitoneum NB Stroma poor. Undif. 25% NO NO
95 4 m F Suprarenal NB Stroma poor. Undif. n.a. YES n.a.
96 3 y F n.a. NB Stroma poor. Undif. 50% n.a. n.a.
97 4 m F Suprarenal NB Stroma poor. Undif. 10% NO n.a.
99 2 m F Thoracic-abdominal NB Stroma poor. Undif. High MKI. 60% n.a. n.a.
102 1 y F Mediastinum NB Stroma poor. Undif. Low MKI. 15% YES NO
F: female. M: man. y: year/years. M: month/months. w: weeks. GN: Ganglioneuroma. GNB: Ganglioneuroblastoma. NB: Neuroblastoma. Dif: 
differentiated. Undif: undiferentiated. MKI: mitosis-karyorrhexis index. MYCN amp.: MYCN amplification. n.a.: data non avaible.BMC Cancer 2006, 6:254 http://www.biomedcentral.com/1471-2407/6/254
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LOH and MSI analysis
Blood and tumor DNA from 21 patients was screened for
LOH and analyzed for MSI using four polymorphic mark-
ers (D3S3507, D3S3615, D3S3624 and D3S3522) located
on chromosome 3p21.
Approximately 50 ng of DNA template was amplified in a
total volume of 25 µl containing 5 pmol of each primer, 2
mM MgCl2, 0,2 mM of each dNTP, 10× reaction buffer
and 1 unit of Biotaq™ DNA polymerase (Bioline Ltd., Lon-
don, UK). For D3S3522 and D3S3615 amplification reac-
tions were first heated to 95°C for 5 min, followed by 32
cycles of 94°C (30 s), 58°C (30 s), and 72°C (30 s). A
final step at 72°C for 10 min was included. The annealing
temperatures used for D3S3624 and D3S3504 were 56°C
and 60°C, respectively.
After amplification, 17 µl of the PCR products were ana-
lyzed by electrophoresis using 15% polyacrylamide gels.
The DNA bands were visualized by ethidium bromide
staining (0,5 µg/ml).
Sodium bisulfite modification
DNA from the 41 tumors and the 12 cell lines was modi-
fied with sodium bisulfite using the CpGenome™ DNA
Modification Kit (Chemicon International, Inc. Temecula,
CA, USA) according to the manufacturer's instructions.
MSP
PCRs were carried out in a final volume of 25 µl contain-
ing 2,5 mM MgCl2, 0,2 mM of each dNTP, 10× reaction
buffer, 10 pmol of each primer, 5% of DMSO, 60 ng of
modified DNA and 1 unit of AmpliTaq Gold™ DNA
polymerase (Applied Biosystems, Foster City, CA, USA).
Annealing temperatures were from 50°C to 66°C. Primers
for RASSF1A amplification were designed by using the
MethPrimer® software [22], and primers for NORE1A,
BLU and CASP8 had been previously described [3,14,23]
(see Table 2).
RT-PCR
One µg of RNA from each cell line was mixed with 1 µl 10
mM dNTPs, and 1 µl 250 µM random primers in a final
volume of 12 µl. After heating to 65°C for 5 min, 4 µl 5×
reaction buffer and 2 µl 0.1 mM DTT were added. The
mixture was incubated at 42°C for 2 min, followed by
addition of 1 µl of Superscript™ II RNA Retrotranscriptase
(Invitrogen™ Life Technologies, Carlsbad, CA). Samples
were incubated at 25° for 10 min, and then at 42°C for 50
min. A final step at 70°C for 15 min was included. cDNAs
were stored at -20°C until their use.
Approximately 75 ng of cDNA was amplified in a total
volume of 25 µl containing 0,2 mM of each dNTP, 2 mM
MgCl2, 10× reaction buffer, 10 pmol of each primer, 5%
of DMSO, and 1 unit of AmpliTaq Gold™ DNA polymer-
ase (Applied Biosystems, Foster City, CA, USA). For BLU
amplification, no DMSO was added and 1 unit of Biotaq™
DNA polymerase (Bioline Ltd., London, UK) was used.
Primers for RASSF1A and TFR amplification were
designed with the Oligo 4.0 software (NBI, Hamel, MN,
USA), and the CASP8 primers were designed using the
Primer Express 2.0 software. Primers used for NORE1A
and BLU PCRs had been previously described[3,14] (see
Table 3). A fragment of the transferrin receptor gene (TFR)
was amplified as an internal control.
Statistical analysis and ethics
Fisher's exact test was applied to screen for any statistical
relationship between LOH at 3p21, promoter hypermeth-
ylation of the RASSF1A, NORE1A, BLU and CASP8 genes
and the clinicopathological tumor data. Also, statistical
correlation between RASSF1A and BLU hypermethyla-
tion, and between RASSF1A and CASP8 hypermethylation
was analyzed. Ethical approval for the study was obtained
from the Ethics Committee of the University of Navarra,
in Pamplona, Spain (ref. 38/2002)
Results
LOH and MSI analysis
LOH and MSI were determined using four polymorphic
markers (D3S3507, D3S3615, D3S3624 and D3S3522)
located on chromosome 3p21. We found LOH at the
markers D3S3507 and D3S3615 in 1 (6%) of 16 and 2
(14%) of 14 neuroblastic tumors, respectively. MSI was
detected for all polymorphic markers studied (Figure 1,
Table 4).
Methylation
RASSF1A was analyzed in 35 neuroblastic tumors and in
12 neuroblastoma cell lines. Hypermethylation of this
gene was detected in 29 (83%) tumors and in all cell lines
(Figure 2, Tables 4 and 5).
BLU hypermethylation was detected in 3 (8%) of 35 neu-
roblastic tumors, and in 7 (66%) neuroblastoma cell lines
(Tables 4 and 5). We did not detect any statistical correla-
tion between RASSF1A and BLU hypermethylation.
Only one (3%) of 34 neuroblastic tumors showed
NORE1A hypermethylation, but 6 (50%) cell lines
showed this alteration (Tables 4 and 5).
CASP8 promoter hypermethylation was studied in a total
of 35 neuroblastic tumors and detected in 21 (60%) of
these. Eleven (92%) of the 12 neuroblastoma cell lines
studied showed hypermethylation of the CASP8 promoter
(Tables 4 and 5). RASSF1A and CASP8 hypermethylation
was linked (Fisher's exact test, p < 0.05).BMC Cancer 2006, 6:254 http://www.biomedcentral.com/1471-2407/6/254
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RT-PCR
We studied the expression of the RASSF1A, BLU, NORE1A
and CASP8 genes in 12 neuroblastoma cell lines by semi-
quantitative RT-PCR (Figure 3, Table 5). RASSF1A showed
lack of expression in all cell lines. BLU was expressed in all
cell lines. NORE1A and CASP8 showed expression in all
cell lines except in IMR-32. In conclusion, gene methyla-
tion was correlated with lack of expression only in the case
of RASSF1A.
Statistical analysis
Fisher's exact test did not reveal any statistical correlation
between the genetic alterations found in tumor samples
and the clinicopathological data.
Discussion
Loss of heterozygosity (monoallelic loss) associated with
hemimethylation (methylation at the promoter of the
same gene in the remaining allele) or with mutation of the
remainder allele, constitute two mechanisms of inactiva-
tion of tumor suppressor genes. A third one might be
hypermethylation of the gene at both alleles.
LOH and MSI are frequent genetic alterations found in
neoplasias. For example, in colorectal cancers, high fre-
quency of LOH is associated with high metastatic poten-
tial[24]. LOH at 12q22-q34 and 14q has been described
in glioblastomas, while MSI is not frequent in these
tumors [25-27].
Allelic losses of chromosome 3p are frequent in many
sporadic cancers, such as lung, colon, nasopharyngeal and
gastrointestinal tract tumors [28-31]. The genetic altera-
tion most frequently found in neuroblastoma is 1p36
allelic loss, which is associated with MYCN amplification
and poor prognosis. LOH at other regions, like 14q, 11q,
9p and 10q, has also been described[32,33]. A recent
report found a correlation between LOH at 3p21 and neu-
roblastoma stages 1 and 4 without MYCN amplifica-
tion[34]. In our study, we analyzed LOH and MSI at
chromosome 3p21, using four polymorphic markers, in
Table 3: Primers and conditions for RT-PCRs.
Gene Primer forward (5'–3') Primer reverse (5'–3') Size (bp) T (°C) Cycles
RASSF1A TCTGTGGCGACTTCATCTGG TTGGGCAGGTAAAAGGAAGT 424 60 35
NORE1A ATCCAGTTGGACTGCAGTCA GGGATTGTCCACAACCATG 450 60 35
BLU GCTTAGCACACACAACCTGC CCTTGGCAAAACTTGTGAGG 233 67 30
CASP8 AGAGAAGCAGCAGCCTTGAAGG AGACAGTATCCCCGAGGTTTGC 160 60 35
TFR GTCAATGTCCCAAACGTCACCAGA ATTTCGGGAATGCTGAGAAAACAGACAGA 298 60 30
Table 2: Primers and conditions for MSPs.
Gene Primer forward (5'–3') Primer reverse (5'–3') Size 
(bp)
T 
(°C)
Cycles
RASSF1A
- U GAGAGTGTGTTTAGTTTTGTTTTTG CCCATACTTCACTAACTTTAAACAC 183 62 38
- M GAGAGCGCGTTTAGTTTCGTTTTC ACCCGTACTTCGCTAACTTTAAACG 184 58 35
NORE1A
- U ATTTATATTTGTGTAGATGTTGTTTGGTAT ACTTTAACAACAACAACTTTAACAACTACA 215 54 40
- M CGTCGTTTGGTACGGATTTTATTTTTTTCGGTTC GACAACTTTAACAACGACGACTTTAACGACTACG 202 62 40
BLU
- U TTTGTGGGTTATAGTTTGAGAAAGTG AACAAATTAACCACACCTACAC 156 60 30
- M TTCGTGGGTTATAGTTCGAGAAAGCG AACGAATTAACCGCGCCTACGC 156 66 30
CASP8
- U TAGGGGATTTGGAGATTGTGA CCATATATCTACATTCAAAACAA 320 53 40
- M TAGGGGATTCGGAGATTGCGA CGTATATCTACATTCGAAACGA 321 50 40
U: unmethylated; M: methylated.BMC Cancer 2006, 6:254 http://www.biomedcentral.com/1471-2407/6/254
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21 neuroblastic tumors, and found LOH and MSI in 14%
of the tumors. Our results are similar to previously pub-
lished data[34,35] that describes LOH and MSI at 3p in a
small percentage of neuroblastic tumors.
Aberrant promoter methylation of tumor suppressor
genes is a mechanism of inactivation described in many
tumors. In neuroblastomas, methylation of several genes,
including MGMT, SLIT2, CD44, FLIP and RASSF1A, has
been described[3,23,36-39]. Moreover, CpG methylation
profiles characterize different clinical subgroups and
strongly correlate with outcome[40,41]. In our study, we
examined the methylation status of the RASSF1A, BLU,
NORE1A and CASP8 genes in 41 neuroblastic tumors and
in 12 neuroblastoma cell lines.
Epigenetic inactivation of RASSF1A has been described in
sporadic tumors such as gliomas, breast, prostate, kidney
and ovarian tumors[11,12,42-44], and also in the pediat-
ric tumors Wilms' tumor, neuroblastoma, medulloblast-
Table 4: LOH/MSI and promoter methylation in 41 neuroblastic tumors.
Tumor Diagnostic LOH/MSI Methylation
D3S3615 D3S3507 D3S3624 D3S3522 RASSF1A NORE1A BLU CASP8
1 G N --------
17 GN n.d. n.d. n.d. n.d. ❍ ---
94 GN n.d. n.d. n.d. n.d. ❍ ---
3 GNB n.d. n.d. n.d. n.d. ❍ ---
5 GNB n.d. - n.d. n.d. ❍ n.a. ❍❍
7 GNB n.d. n.d. n.d. n.d. n.a. n.a. n.a. n.a.
8 GNB MSI MSI MSI MSI ❍ --❍
9 GNB n.d. n.d. n.d. n.d. ❍ --❍
10 GNB n.d. n.d. n.d. n.d. ● ---
61 G N Bn . d . n . d . n . d . n . d . ----
82 G N Bn . d . - n . d . n . d . ----
83 GNB n.d. n.d. n.d. n.d. ❍❍ - ❍
86 GNB n.d. n.d. n.d. n.d. ● - ❍❍
92 G N B ----❍ --❍
107 GNB n.d. n.d. n.d. n.d. ❍ --❍
12 NB n.d. n.d. n.d. n.d. ❍ n.a. - ❍
13 NB n.d. n.d. n.d. n.d. ❍ --❍
14 NB n.d. n.d. n.d. n.d. n.a. n.a. n.a. n.a.
15 NB n.d. n.d. n.d. n.d. n.a. n.a. n.a. n.a.
16 NB n.d. n.d. n.d. n.d. n.a. n.a. n.a. n.a.
18 NB n.d. n.a. n.a. n.a. ❍ ---
33 NB n.d. n.d. n.d. n.d. ❍ ---
37 NB n.d. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
34 N B ----n . a . n . a . n . a . n . a .
45 NB LOH LOH - - ❍ --❍
48 N B ----● --❍
51 NB n.a. n.a. n.a. n.a. ❍ --❍
52 NB n.d. n.d. n.d. n.d. ❍ ---
63 N B ----❍ --❍
64 NB MSI - MSI MSI ❍ - ❍❍
73 NB n.a. n.a. n.a. n.a. ❍ --❍
77 NB LOH - MSI LOH ❍ --❍
85 NB n.d. n.d. n.d. n.d. ❍ - ❍ -
87 NB n.d. n.d. n.d. n.d. ❍ --❍
90 N B ----- - - ❍
91 N B ----❍ --❍
95 N B ----❍ --❍
96 N B n . d . n . d . n . d . n . d . ----
97 N B ----❍ ---
99 NB n.d. n.d. n.d. n.d. ❍ ---
102 N B ----❍ ---
GN: ganglioneuroma; GNB: ganglioneuroblastoma; NB: neuroblastoma; ● : Methylated; ❍ : Hemimethylated;-: unmethylated, no LOH/MSI; n.d.: not 
determined (due to lack of blood specimens from patients); n.a.: non amplified.BMC Cancer 2006, 6:254 http://www.biomedcentral.com/1471-2407/6/254
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oma, rhabdomyosarcoma and retinoblastoma[10,45]. In
neuroblastoma several studies have shown a high fre-
quency of RASSF1A methylation. Yang et al. found a sta-
tistical correlation between RASSF1A methylation and
poor outcome[36], while Wong et al.[46] did not detect
any link between clinical data (age, tumor size and out-
come) and methylation of this gene. Furthermore, they
found RASSF1A methylation in adjacent non-tumor tis-
sues, suggesting that this epigenetic change is potentially
an early and critical event in childhood neoplasia. In our
study, we found RASSF1A hypermethylation in 83% of
the tumor samples. RASSF1A was the only gene for which
we could see a significant correlation between promoter
hypermethylation and reduction or lack of expression. All
neuroblastoma cell lines analyzed showed hypermethyla-
tion of RASSF1A and none expressed the gene.
In order to determine if RASSF1A methylation was due to
global methylation of the chromosomal region 3p21.3, or
whether it was gene specific, we analyzed BLU promoter
methylation in the neuroblastic tumor samples and neu-
roblastoma cell lines. Agathanggelou et al. reported a BLU
methylation frequency of 41% in neuroblastoma tumors
and of 86% in neuroblastoma cell lines[3]. We found BLU
methylation in 8% of the tumor samples and in 66% of
the cell lines. All cell lines analyzed expressed the
RASSF1A gene. Our results suggest that methylation of
RASSF1A and BLU are independent events. Agathangge-
lou et al. also found no correlation between methylation
of RASSF1A and BLU in neuroblastoma and SCLC, while
in NSCLC, they described a global methylation pattern of
the 3p21.3 region[3].
The NORE1A gene is frequently methylated in lung,
breast, colon, kidney and Wilms' tumors, while no muta-
tion of this gene has been described in cancer[14,16]. We
found NORE1A methylation in 3% of the tumor samples
and in 50% of the neuroblastoma cell lines. Only the
IMR-32 cell line showed lack of NORE1A expression. The
difference in methylation percentage between tumors and
cell lines suggests that NORE1A methylation appears later
in tumor progression. An alternative explanation is that
cell culture induces methylation changes[47]. To our
knowledge, this is the first report to show NORE1A pro-
moter methylation and lack of expression in neuroblast-
oma.
The main apoptotic defect found in neuroblastomas is the
down-regulation of the CASP8 gene. Aberrant methyla-
tion of this gene has been reported in the childhood neo-
plasias medulloblastoma, retinoblastoma and
neuroblastoma[19,48]. Several studies suggest that CASP8
Table 5: Promoter hypermethylation and expression in neuroblastoma cell lines.
Cell line Methylation Expression
RASSF1A BLU NORE1A CASP8 RASSF1A BLU NORE1A CASP8
Kelly ●❍❍❍ -+ - / + +
SIMA ●❍ - ❍ -+ - / + - / +
MC-IXC ● -- ❍ -+++
SK-N-FI ● -- ❍ -+ - / + +
SH-SY5Y ●❍ - ❍ -+++
SK-N-SH ●❍ - ❍ -+ - / + +
SK-N-MC ● - ❍ - -+++
IMR-32 ●❍❍❍ -+--
MHH-NB-11 ●❍❍❍ -+ - / + - / +
SK-N-Be(2) ● -- ❍ -+ - / + +
SK-N-DZ ●❍❍❍ - -/+ -/+ -/+
BE(2)C ● - ❍❍ -+ - / + +
● : Methylated; ❍ : Hemimethylated;-: unmethylated/lack of expression; +: expression; -/+: low expression.
Loss of heterozygosity study at D3S3522 polymorphic  marker in neuroblastic tumors Figure 1
Loss of heterozygosity study at D3S3522 polymorphic 
marker in neuroblastic tumors. PCR products were run in a 
15% polyacrylamide gel and visualized after ethidium bromide 
staining (0.5 µg/ml) T: DNA from tumor tissue; N: DNA 
from peripheral blood of the same patient; M1/M2: 10 bp 
DNA ladder/1 Kb Plus DNA ladder (Invitrogen™ Life and 
Technologies, Carlsbad, CA, USA). Sample number 64 
showed microsatellite instability.BMC Cancer 2006, 6:254 http://www.biomedcentral.com/1471-2407/6/254
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promoter methylation is associated with MYCN amplifi-
cation, while other reports claim that there is no correla-
tion between these genetic alterations[21,49-51]. We
found CASP8 promoter methylation in 60% of the neu-
roblastic tumors and in 92% of the neuroblastoma cell
lines. All cell lines, except IMR-32, showed expression of
the CASP8 gene. In this study, we did not find a correla-
tion between CASP8 methylation and MYCN amplifica-
tion, but we found a statistical relationship between
CASP8 and RASSF1A promoter methylation, as previously
described in different pediatric tumors by Harada et al.
[48].
Conclusion
Our results suggest that: 1) LOH at 3p21 appears in a
small percentage of neuroblastomas, suggesting that a
candidate tumor suppressor gene of neuroblastic tumors
is not located in this region, and 2) promoter hypermeth-
ylation of RASSF1A and CASP8 is frequent in neuroblast-
omas.
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Expression of RASSF1A, NORE1A, BLU and CASP8 in neu- roblastoma cell lines determined by RT-PCR and visualized in  2% agarose gels stained with 0.1 µg/ml ethidium bromide Figure 3
Expression of RASSF1A, NORE1A, BLU and CASP8 in neu-
roblastoma cell lines determined by RT-PCR and visualized in 
2% agarose gels stained with 0.1 µg/ml ethidium bromide. M: 
1 Kb Plus DNA Ladder (Invitrogen™ Life and Technologies, 
Carlsbad, CA, USA); 1: Normal human lung cDNA; 2: Kelly; 
3: BE(2)-C; 4: SK-N-MC; 5: SK-N-FI; 6: SK-N-Be(2); 7: IMR-
32; 8: MC-IXC; 9: SH-SY5Y; 10: SK-N-SH; 11: MHH-NB-11; 
12: SIMA; 13: SK-N-DZ; 14: genomic DNA; 15: water. A 
fragment of the transferrin receptor gene was amplified as an 
internal control.
Promoter methylation analysis of RASSF1A (A), NORE1A  (B), BLU (C) and CASP8 (D) in neuroblastic tumors (B, C  and D) and cell lines (A), determined by MSP and visualized in  2.5% agarose gels stained with 0.1 µg/ml ethidium bromide Figure 2
Promoter methylation analysis of RASSF1A (A), NORE1A 
(B), BLU (C) and CASP8 (D) in neuroblastic tumors (B, C 
and D) and cell lines (A), determined by MSP and visualized in 
2.5% agarose gels stained with 0.1 µg/ml ethidium bromide. 
U/M: unmethylated/methylated; M: 1 Kb Plus DNA Ladder 
(Invitrogen™ Life and Technologies, Carlsbad, CA, USA); B: 
DNA obtained from blood of a normal donor; IMD (in vitro 
methylated DNA): positive control, CpGenome™ Universal 
Methylated DNA (Chemicon International, Inc., Temecula, 
CA, USA);-: water (no DNA negative control). A) 2: SH-
SY5Y; 3: SK-N-SH; 4: SK-N-MC; 5: IMR-32; 6: MHH-NB-11; 
7: SK-N-Be(2); 8: SK-N-DZ; 9: BE(2)C. B), C), and D) Num-
bers on top of each well correspond to DNA from different 
neuroblastic tumors analyzed.BMC Cancer 2006, 6:254 http://www.biomedcentral.com/1471-2407/6/254
Page 9 of 10
(page number not for citation purposes)
LOH: loss of heterozygosity
MSI: microsatellite instability
MSP: methylation specific PCR
NSCLC: non small cell lung cancer
SCLC: small cell lung cancer
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